In its Form 8-K dated June 26, 2025, Incyte Corporation (INCY) disclosed a major leadership transition.
Retirement of CEO Hervé Hoppenot: Mr. Hoppenot stepped down as President & Chief Executive Officer effective June 26, 2025, but will remain on the Board and act as special advisor for up to one year. Compensation during the advisory period equals his current $1,395,731 annual base salary for six months and 50% of that rate for the subsequent six months, plus a prorated 2025 cash bonus. He also received equity grants of 6,016 RSUs, 18,438 stock options, and 18,050 performance shares (0-200% payout, 3-year TSR goals), all of which will continue to vest post-transition, subject to customary covenants.
Appointment of William J. Meury as President & CEO: Effective the same date, Mr. Meury (age 57) joins the company and its Board. His background includes CEO roles at Anthos Therapeutics (2024-2025) and Karuna Therapeutics (2023-2024), senior commercial leadership at Allergan, and over 30 years in biopharma commercialization.
Compensation package for Mr. Meury: • Initial base salary $1,250,000 • Target annual bonus 100% of salary (pro-rated for 2025) • Time-based RSUs for 36,101 shares (25% per year over four years) • Options for 110,630 shares (25% after one year, then monthly over 36 months) • 108,303 performance shares (0-200% payout, 3-year TSR goals) • One-time sign-on PSU award for 125,000 shares (0-400% payout tied to multi-year stock-price hurdles) • Relocation and commuting benefits. Severance terms include 1.5× salary+target bonus if terminated without Cause or he resigns for Good Reason outside a change-of-control window, plus partial accelerated vesting of equity.
Governance changes: Lead Independent Director Julian C. Baker becomes Chairman of the Board.
These actions signal a planned but material shift in senior leadership, accompanied by significant equity-based incentives designed to align the incoming CEO with long-term shareholder value.